Novartis's drug sharply lowered lipoprotein(a), a cardiovascular risk marker, but failed to reduce heart attacks or strokes. The result challenges the assumption that lowering the marker alone will prevent cardiovascular events.
9:50 AMStat News5 stories from 2 sources
Cardiovascular drug bets meet harder outcome tests
Day’s Recap
Supporting Articles
Cardiologists say the failure of Novo Nordisk's anti-inflammatory cardiovascular drug does not disprove the role of inflammation in heart disease. They intend to continue testing other anti-inflammatory approaches and targets.
9:35 AMStat News
BIO has joined a legal challenge to a Medicare pilot that would tie certain drug prices to those paid in comparable foreign countries. The pilot tests President Trump's most-favored-nation approach to drug pricing, but its direct reach is expected to remain limited.
11:57 AMStat News9:50 AMStat News
STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
Summary
Novartis's drug sharply lowered lipoprotein(a), a cardiovascular risk marker, but failed to reduce heart attacks or strokes. The result challenges the assumption that lowering the marker alone will prevent cardiovascular events.
The decisive shift is that Lp(a) reduction did not translate into better clinical outcomes. Novartis
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The result could redirect cardiovascular drug development away from promising markers that lack proven clinical benefit.
9:35 AMStat News
STAT+: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories
Summary
Cardiologists say the failure of Novo Nordisk's anti-inflammatory cardiovascular drug does not disprove the role of inflammation in heart disease. They intend to continue testing other anti-inflammatory approaches and targets.
The negative trial weakens confidence in this particular drug and mechanism, not necessarily the broader
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The field is shifting from whether inflammation matters to which inflammatory pathways can be targeted safely and effectively.
11:57 AMStat News
STAT+: BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries
Summary
BIO has joined a legal challenge to a Medicare pilot that would tie certain drug prices to those paid in comparable foreign countries. The pilot tests President Trump's most-favored-nation approach to drug pricing, but its direct reach is expected to remain limited.
BIO's legal involvement adds industry weight to a challenge that could delay or narrow the
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The lawsuit could shape whether the administration can advance international drug-price controls without new legislation.
Other Developments
A curated list of other prominent stories from this day.
The article examines the difficulty of lowering blood pressure in people recovering from stroke or living with diabetes. It describes ongoing efforts to improve hypertension treatment and reduce the risks associated with persistently high blood pressure.
4:39 PMStat News
A study tracking participants for up to 43 years found that people who drank two to three cups of caffeinated coffee daily had lower dementia risk and better cognitive performance. The association held across genetic-risk groups, while decaffeinated coffee showed no comparable link.
5:16 AMScienceDaily4:39 PMStat News
Lowering blood pressure after stroke or with diabetes poses challenges, in research and practice
Summary
The article examines the difficulty of lowering blood pressure in people recovering from stroke or living with diabetes. It describes ongoing efforts to improve hypertension treatment and reduce the risks associated with persistently high blood pressure.
The central challenge is not identifying high blood pressure as a major risk, but determining
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Blood-pressure treatment decisions can materially change the risk of recurrent stroke, heart disease, and other complications for millions of high-risk patients.
5:16 AMScienceDaily
Drinking 2–3 cups of coffee a day linked to dramatically lower dementia risk
Summary
A study tracking participants for up to 43 years found that people who drank two to three cups of caffeinated coffee daily had lower dementia risk and better cognitive performance. The association held across genetic-risk groups, while decaffeinated coffee showed no comparable link.
The key finding is an association, not proof that coffee prevents dementia. If confirmed, moderate
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The study points to a common, potentially modifiable behavior that may be linked to long-term cognitive health.
Make it yours
Build Your First Pass.
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!